Tecelra, afamitresgene autoleucel

Tecelra (afamitresgene autoleucel) is an FDA-approved cell therapy for people aged 12 and older with advanced synovial sarcoma who meet specific HLA and MAGE-A4 test criteria. Not available where you live? Your doctor may be able to request it by named-patient import. Reserve Meds coordinates the US supply and paperwork and quotes your costs in writing first.

Named-patient access overview. Tecelra is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.

Ask about Tecelra

Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.

We reply on WhatsApp.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

About Tecelra

Tecelra (afamitresgene autoleucel) is manufactured by Adaptimmune and indicated for Synovial sarcoma. It is a TCR-T (MAGE-A4) approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.

Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.

How Reserve Meds coordinates Tecelra

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Tecelra for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Tecelra is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Clinical trials and expanded access

On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list afamitresgene autoleucel as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.

Expanded access records for afamitresgene autoleucel that were marked “Available” on 17 October 2026:

Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.

Access by country

Reserve Meds publishes a detailed country deep-dive for Tecelra in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Start a request for Tecelra

Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.

Ask about a medicine Or message us on WhatsApp

Frequently asked questions

How can I get Tecelra if it is not approved or available in my country?

Reserve Meds coordinates US-sourced Tecelra for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.

Can I access Tecelra through a named-patient import?

Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Tecelra. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.

Do I need a prescription to access Tecelra through Reserve Meds?

Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.

How does Reserve Meds deliver Tecelra to a patient?

Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Tecelra to your treating physician or hospital pharmacy, with appropriate handling for the product.

How long does it take, and what does Tecelra cost through Reserve Meds?

After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.

How do I start a request for Tecelra?

Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.

WhatsApp